Raynaud, FI and Eccles, S and Clarke, PA and Hayes, A and Nutley, B and Alix, S and Henley, A and Di-Stefano, F and Ahmad, Z and Guillard, S and Bjerke, LM and Kelland, L and Valenti, M and Patterson, L and Gowan, S and de Haven Brandon, A and Hayakawa, M and Kaizawa, H and Koizumi, T and Ohishi, T and Patel, S and Saghir, N and Parker, P and Waterfield, M and Workman, P (2008) Pharmacologic characterization of a potent inhibitor of class I phosphatidylinositide 3-kinases. Cancer Research , 67 (12) 5840 - 5850.
Full text not available from this repository.
Extensive evidence implicates activation of the lipid phosphatidylinositide 3-kinase (PI3K) pathway in the genesis and progression of various human cancers. PI3K inhibitors thus have considerable potential as molecular cancer therapeutics. Here, we detail the pharmacologic properties of a prototype of a new series of inhibitors of class I PI3K. PI103 is a potent inhibitor with low IC50 values against recombinant PI3K isoforms p110alpha (2 nmol/L), p110beta (3 nmol/L), p110delta (3 nmol/L), and p110gamma (15 nmol/L). PI103 also inhibited TORC1 by 83.9% at 0.5 micromol/L and exhibited an IC50 of 14 nmol/L against DNA-PK. A high degree of selectivity for the PI3K family was shown by the lack of activity of PI103 in a panel of 70 protein kinases. PI103 potently inhibited proliferation and invasion of a wide variety of human cancer cells in vitro and showed biomarker modulation consistent with inhibition of PI3K signaling. PI103 was extensively metabolized, but distributed rapidly to tissues and tumors. This resulted in tumor growth delay in eight different human cancer xenograft models with various PI3K pathway abnormalities. Decreased phosphorylation of AKT was observed in U87MG gliomas, consistent with drug levels achieved. We also showed inhibition of invasion in orthotopic breast and ovarian cancer xenograft models and obtained evidence that PI103 has antiangiogenic potential. Despite its rapid in vivo metabolism, PI103 is a valuable tool compound for exploring the biological function of class I PI3K and importantly represents a lead for further optimization of this novel class of targeted molecular cancer therapeutic.
|Title:||Pharmacologic characterization of a potent inhibitor of class I phosphatidylinositide 3-kinases.|
|UCL classification:||UCL > School of Life and Medical Sciences > Faculty of Life Sciences > Biosciences (Division of)|
Archive Staff Only: edit this record